Director, Integrated Product Medical Lead

YOUR TASKS AND RESPONSIBILITIES

The Integrated Product Medical Lead (IPML) is crucial for advancing the Oncology early development portfolio. As an IPML, you create a significant impact through the successful progression of global development programs and the expansion of our pipeline. You set the vision and strategic direction for assigned programs, ensuring a medically and clinically sound end-to-end development strategy for our products across various modalities, biologies, and indications, representing the full value chain from pre-D1 up to hand-over to late-stage drug development.

You build an end-to-end clinical strategy and are responsible for executing development programs on behalf of Early Clinical Development Oncology (ECDO), providing clinical-scientific leadership for one or more global development programs with full decision-making authority. Collaborating with cross-functional IPT members, you drive the creation and maintenance of a target product and target value profile to maximize the clinical success of development programs, significantly shaping the value of the product.

You co-lead the incorporation of novel assets into the pipeline through supporting internal and external innovation efforts. Additionally, you play a vital role in shaping functional excellence within ECDO by driving core project, people, and innovative clinical development topics under a peer-reviewed setting, pushing the boundaries of drug development in collaboration with internal and external researchers.

Key tasks:

• Act as the clinical leader and primary clinical representative for global programs, ensuring high quality and speed of functional deliverables.
• Develop a clinical vision for addressing unmet medical needs, considering the molecule's scientific hypothesis.
• Accountable for timely delivery of milestones, mitigating roadblocks, and empowered to take decisions to effectively execute the clinical strategy.
• Support preclinical evaluation and validation of new oncology assets in line with the Research and Early Development Oncology (RED ONC) strategy.
• Guide preclinical asset development to enable informed clinical development, facilitating go/no-go decision making.
• Review key study documents, ensuring alignment with clinical development plans and target product profiles.
• Provide comprehensive knowledge of the scientific, development, and regulatory landscape to enable state-of-the-art early precision drug development.
• Proactively interact with academic and industry partners, health authorities, key opinion leaders, and patient advocacy groups.
• Lead and drive ECDO-initiated strategic initiatives in support of overall ECDO, RED-ONC, Oncology, and Bayer strategy.
• Independently lead self-empowered matrix teams, promoting a creative and innovation-friendly collaboration between clinicians and scientists.
• Foster a culture of ownership and empower others, driving peer accountability across portfolio deliverables.

WHO YOU ARE

• Medical excellence: M.D. with 5+ years in direct patient care and board certification within oncology/hematology or associated subspecialties.
• Scientific excellence demonstrated by a track record of relevant research documented in peer-reviewed publications.
• Outstanding drug development expertise with 3-5 years of experience, including 2+ years in early drug development.
• Expertise across different biologies and modalities, including small and large molecules.
• Relevant global health authority interactions and current knowledge of regulatory review and responses.
• Ability to independently develop a sound medical strategy and teach others to do so.
• Strong communication and leadership skills, strategic thinking, and good business and external trends insights.
• High energy with focus and vision; self-motivated with a high sense of ownership and proactive, solution-oriented approach.
• Fluency in English is mandatory; command of a second major European language, especially German, would be an asset.